WO2013115636A1 - Composition pour le traitement et/ou la prévention de maladie du foie gras - Google Patents

Composition pour le traitement et/ou la prévention de maladie du foie gras Download PDF

Info

Publication number
WO2013115636A1
WO2013115636A1 PCT/MY2013/000018 MY2013000018W WO2013115636A1 WO 2013115636 A1 WO2013115636 A1 WO 2013115636A1 MY 2013000018 W MY2013000018 W MY 2013000018W WO 2013115636 A1 WO2013115636 A1 WO 2013115636A1
Authority
WO
WIPO (PCT)
Prior art keywords
tocotrienol
fld
liver
composition
alcoholic
Prior art date
Application number
PCT/MY2013/000018
Other languages
English (en)
Inventor
Enrico MAGOSSO
Original Assignee
Universiti Sains Malaysia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiti Sains Malaysia filed Critical Universiti Sains Malaysia
Publication of WO2013115636A1 publication Critical patent/WO2013115636A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Definitions

  • drug-induced liver disease is used to describe those instances in which an active agent has caused injury to the liver.
  • Drug-induced liver injury may account for as many as 10 percent of hepatitis cases in adults overall, 40 percent of hepatitis cases in adults over fifty years old, and 25 percent of cases of fulminant liver failure.
  • Certain active agents such as glucocorticoids, synthetic estrogens, amiodarone, tamoxifen and valproic acid, for example, have been associated with fatty liver.
  • the tocotrienol tail has three double bonds.
  • Homologs of tocotrienols may be chemically synthesized. Experimental details are provided on a new tocotrienol synthesis which provides stereochemical ⁇ pure materials.
  • the study is a completely randomised interventional study.
  • Animals (Mus musculus or Swiss albino mice, sourced from the animal facilities of Universiti Sains Malaysia (Penang, Malaysia) were randomised into 3 groups of treatment with the first group (Control) fed a standard diet of commercially sourced P702 pellets (Gold Coin, Port Klang, Malaysia), the second group fed high fat-high fructose (HFF) diet comprising 50% P702, 30% clarified butter and 20% fructose and the third group a high-fat-high fructose plus tocotrienols (HFF- T3) diet comprising 50% P702, 30% clarified butter and 20% fructose plus mixed tocotrienols (Tocomin, Carotech, Ipoh, Malaysia).
  • HFF high fat-high fructose
  • HFF- T3 diet high-fat-high fructose plus tocotrienols
  • the animals assigned to the control group received throughout the study duration a standard diet consisting in P702 pellets (Gold Coin, Port Klang, Malaysia).
  • the HFF diet group received a in-house developed and extruded feed consisting of a mixture of standard P702 pellets powder, dairy fat (Kee Wee, Penang, Malaysia) and fructose (HMBG Chemicals, Hamburg, Germany).
  • the HFF-T3 feed was prepared from the HFF ingredients and enriched with tocotrienols (Tocomin50%, Carotec, Ipoh, Malaysia).
  • the in- house feed was prepared weekly and stored at -20 ⁇ until dispensed. Details of the composition of the developed feed is given in table 2 below
  • tocotrienol was extracted from homogenised liver grafts weighing 250 pg each by addition of 1 ml of ethanol, followed by 4 ml of extraction solvent consisting of hexane:ethyl acetate (95:5 v/v).
  • the prepared samples were first vortexed for 2 min then centrifuged at 3500 rpm for 10 min.
  • a 50 ⁇ aliquot of supernatant was injected into a Waters (Milford, MA, USA) high-performance liquid chromatography (HPLC) system, consisting of autosampler 717 Plus, separation module 600Control and fluorescent detector 2475.
  • the detector excitation wavelength was set 296 nm and the emission wavelength was set 330 nm.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne au moins un procédé pour traiter, prévenir, atténuer, réduire ou retarder l'apparition de la maladie du foie gras (FLD) en utilisant le tocotriénol ou un dérivé de celui-ci ou un mélange de ceux-ci.
PCT/MY2013/000018 2012-02-02 2013-01-31 Composition pour le traitement et/ou la prévention de maladie du foie gras WO2013115636A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MYPI2012000461 2012-02-02
MYPI2012000461 2012-02-02

Publications (1)

Publication Number Publication Date
WO2013115636A1 true WO2013115636A1 (fr) 2013-08-08

Family

ID=48905587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MY2013/000018 WO2013115636A1 (fr) 2012-02-02 2013-01-31 Composition pour le traitement et/ou la prévention de maladie du foie gras

Country Status (1)

Country Link
WO (1) WO2013115636A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030007961A1 (en) * 2001-06-22 2003-01-09 Wilburn Michael D. Orthomolecular vitamin E derivatives
WO2004096137A2 (fr) * 2003-04-08 2004-11-11 Barrie Tan Compositions d'extrait de rocou contenant des geranylgeraniols et modes d'utilisation
WO2005009135A1 (fr) * 2003-04-10 2005-02-03 Barrie Tan Compositions d'extrait de rocou comprenant des tocotrienols et des tocopherols et procedes d'utilisation
WO2011027344A2 (fr) * 2009-09-01 2011-03-10 Hadasit Medical Research Services And Development Ltd. Combinaison de vitamine e et de bêta-glycosphingolipides dans des compositions, méthodes de prévention et de traitement des troubles hépatiques
WO2011097273A1 (fr) * 2010-02-02 2011-08-11 Martek Biosciences Corporation Méthodes et compositions permettant le traitement de la stéatose hépatique non alcoolique au moyen d'acide docosahexaénoïque et de n-acétyl-l-cystéine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030007961A1 (en) * 2001-06-22 2003-01-09 Wilburn Michael D. Orthomolecular vitamin E derivatives
WO2004096137A2 (fr) * 2003-04-08 2004-11-11 Barrie Tan Compositions d'extrait de rocou contenant des geranylgeraniols et modes d'utilisation
WO2005009135A1 (fr) * 2003-04-10 2005-02-03 Barrie Tan Compositions d'extrait de rocou comprenant des tocotrienols et des tocopherols et procedes d'utilisation
WO2011027344A2 (fr) * 2009-09-01 2011-03-10 Hadasit Medical Research Services And Development Ltd. Combinaison de vitamine e et de bêta-glycosphingolipides dans des compositions, méthodes de prévention et de traitement des troubles hépatiques
WO2011097273A1 (fr) * 2010-02-02 2011-08-11 Martek Biosciences Corporation Méthodes et compositions permettant le traitement de la stéatose hépatique non alcoolique au moyen d'acide docosahexaénoïque et de n-acétyl-l-cystéine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YACHI, R. ET AL.: "Protective Effects of Vitamin E Analogs against Carbon Tetrachloride-Induced Fatty Liver in Rats", J. CLIN. BIOCHEM. NUTR., vol. 47, September 2010 (2010-09-01), pages 148 - 154, XP055078787 *

Similar Documents

Publication Publication Date Title
US7862840B2 (en) Kiwi extract
Lee et al. 3-O-Glucosylation of quercetin enhances inhibitory effects on the adipocyte differentiation and lipogenesis
US20070088078A1 (en) Methods for managing adipocyte fat accumulation
Lee et al. Natural products and body weight control
Altiner et al. Effect of the antiobesity agent garcinia cambogia extract on serum lipoprotein (a), apolipoproteins a1 and b, and total cholesterol levels in female rats fed atherogenic diet.
KR20070050433A (ko) 리파아제 저해제
CN114340604A (zh) Cbd组合物
JP5528025B2 (ja) Ｔｇ合成抑制剤
US20210230175A1 (en) Methods of making low odor choline salts of an organic compound
US20170095428A1 (en) Agent for improving glucose tolerance disorder
US20200230102A1 (en) Composition and medical product for reducing body weight and body fat, and use of said product
WO2013115636A1 (fr) Composition pour le traitement et/ou la prévention de maladie du foie gras
US20040097429A1 (en) Method for the reduction of the mammalian appetite
US20080279967A1 (en) Composition and method for increasing the metabolism of free fatty acids and facilitating a favorable blood lipid
US20090214682A1 (en) Composition and methods for weight loss in a subject
AU2020277116A1 (en) Composition for reducing weight and reducing body fat and pharmaceutical product and application thereof
WO1994027629A1 (fr) Procede de maitrise de l'appetit et de traitement de l'obesite
JP2020535222A (ja) 満腹および／または食欲に関与するペプチドレベルの調節による体重管理のための組成物
CN114177185B (zh) 一种用于降低胆固醇与预防心血管疾病的药物组合物
KR101719015B1 (ko) 프루네틴을 유효성분으로 함유하는 비만 또는 대사성 질환의 예방 또는 치료용 약학적 조성물
US20240058300A1 (en) Tocotrienol compositions and methods to treat non-alcoholic steatohepatitis
KR20230047927A (ko) 커피체리 추출물을 포함하는 대사증후군의 예방, 개선 또는 치료용 조성물
WO2018042291A1 (fr) Composition pour le traitement et la prévention d'infections virales
TW202112363A (zh) 一種安卓錠用於製備一預防或治療非酒精性脂肪肝病的藥物之用途
JP2006083106A (ja) 血中中性脂肪濃度上昇抑制作用を有する薬剤及び飲食物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13743504

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 20-11-2014)

122 Ep: pct application non-entry in european phase

Ref document number: 13743504

Country of ref document: EP

Kind code of ref document: A1